Karthik Radhakrishnan insider trades: Monopar Therapeutics (MNPR) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Karthik reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 28, 2024 | MNPR | ↑ Buy | 1,550 | $16.25 | $25K | Direct | Oct 30, 2024 (2d) |
| Dec 18, 2013 | OPXA | ↑ Buy | 8,000 | $1.70 | $14K | Direct | Dec 18, 2013 (0d) |
| Aug 8, 2013 | OPXA | ↑ Buy | 50,000 | $1.50 | $75K | Direct | Aug 9, 2013 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other MNPR insiders
Open-market trades in the last 12 months
About Karthik Radhakrishnan's insider trades
Karthik Radhakrishnan is Chief Financial Officer at Monopar Therapeutics (MNPR). Since Aug 8, 2013, Karthik has reported 3 open-market purchases worth $114K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (4 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MNPR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.